EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies

Tomohiro Kamimura iD, Neil Hounslow iD, Hideki Suganami iD, Ryohei Tanigawa iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13900 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Tomohiro Kamimura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs Department I, Kowa Company, Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cross-Over Studies, Butyrates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kowa Company, Ltd., Kowa Research Europe Co., Ltd., Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elevated triglyceride levels are associated with an increased risk of cardiovascular events despite guideline‐based statin treatment of low‐density lipoprotein cholesterol. Peroxisome proliferator‐activated receptor α (PPARα) agonists exert a significant triglyceride‐lowering effect. However, combination therapy of PPARα agonists with statins poses an increased risk of rhabdomyolysis, which is rare but a major concern of the combination therapy. Pharmacokinetic interaction is suspected to be a contributing factor to the risk. To examine the potential for combination therapy with the selective PPARα modulator (SPPARMα) pemafibrate and statins, drug–drug interaction studies were conducted with open‐label, randomized, 6‐sequence, 3‐period crossover designs for the combination of pemafibrate 0.2 mg twice daily and each of 6 statins once daily: pitavastatin 4 mg/day ( n = 18), atorvastatin 20 mg/day ( n = 18), rosuvastatin 20 mg/day ( n = 29), pravastatin 20 mg/day ( n = 18), simvastatin 20 mg/day ( n = 20), and fluvastatin 60 mg/day ( n = 19), involving healthy male volunteers. The pharmacokinetic parameters of pemafibrate and each of the statins were similar regardless of coadministration. There was neither an effect on the systemic exposure of pemafibrate nor a clinically important increase in the systemic exposure of any of the statins on the coadministration although the systemic exposure of simvastatin was reduced by about 15% and its open acid form by about 60%. The HMG‐CoA reductase inhibitory activity in plasma samples from the simvastatin and pemafibrate combination group was about 70% of that in the simvastatin alone group. In conclusion, pemafibrate did not increase the systemic exposure of statins, and vice versa, in healthy male volunteers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsHydroxymethylglutaryl-CoA Reductase InhibitorsCross-Over StudiesButyratesHealthy VolunteersBenzoxazolesHumansMaleAdultYoung AdultMiddle AgedPPAR alpha

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidButyratesBenzoxazolesPPAR alpha

Autor:innen und Institutionen

  • Medical Affairs Department I, Kowa Company, Ltd., Tokyo, Japan.
  • Kowa Pharmaceutical Europe Co., Ltd., Wokingham, UK.
  • Global Data Science Center, Kowa Company, Ltd., Tokyo, Japan.
  • Global Clinical Development Department, Kowa Company, Ltd., Tokyo, Japan.

ORCID-Profile: Tomohiro Kamimura, Neil Hounslow, Hideki Suganami, Ryohei Tanigawa

Förderung

  • Kowa Company, Ltd.
  • Kowa Research Europe Co., Ltd.
  • Kowa Company

Zitieren

APA

Kamimura, T., Hounslow, N., Suganami, H., & Tanigawa, R. (2024). Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies. Clinical and Translational Science. https://doi.org/10.1111/cts.13900

Vancouver

Kamimura T, Hounslow N, Suganami H, Tanigawa R. Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies. Clinical and Translational Science. 2024. doi:10.1111/cts.13900

BibTeX
@article{Kamimura2024,
  author = {Kamimura, Tomohiro and Hounslow, Neil and Suganami, Hideki and Tanigawa, Ryohei},
  title = {Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13900}
}
Kostenlos starten →